Medical Affairs Reputations: HIV (US)

Medical Affairs Reputations: HIV (US)

Code: FW-21072016-39 | Published: May-2016 | Pages: 0 | FirstWord
Price :

* Required Fields



HIV: Hard work is paying off for the top 2 medical affairs teams in the US. How is your team doing?

In the past 6 months, the medical affairs teams for two leading HIV treatments reached more doctors than any other team—and earned top marks for delivering the services doctors want most.

No wonder their overall satisfaction scores are at least double that of their closest rival.

See how your team compares in Medical Affairs Reputations: HIV.

You’ll learn how infectious disease specialists rate the teams for 8 major HIV treatments, whether they’re satisfied with your team’s performance, and where your team needs improvement.

Answering Key Questions about Medical Affairs Teams for 8 Major HIV Drugs

Evotaz (atazanavir/cobicistat; BMS/Gilead): Does Evotaz’s team do a better job of providing information or responding promptly to inquiries?
Intelence (etravirine; Janssen Pharma): What’s the one area where Intelence’s team outperforms the top 3 teams?
Isentress (raltegravir; Merck & Co.): Isentress’ team outperforms every other team in two areas. What are they?
Selzentry (maraviroc; ViiV Healthcare): Is Selzentry’s team doing a better job of providing scientific information or competitive information?
Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead): Which teams earn higher satisfaction scores than Stribild’s in the areas most important to doctors?
Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare): Which team is more likely to have frequent interactions with doctors, Triumeq’s or Intelence’s?
Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead): Which team’s overall quality score is nearly double Truvada’s?
Viread (tenofovir disoproxil fumarate; Gilead): Does Viread’s team score higher for providing information about trials or supporting workshops and conferences?

Top Takeaways

Top 2 brands have a commanding lead: Their teams’ overall quality scores are at least twice as high as any competitor’s. The same two brands have the leading teams in the EU5 market too.
Activity pays off: Teams that interact more with doctors tend to have higher overall quality scores. The two leading teams have the most interactions by far.
Clear unmet need in the market: Doctors are most likely to use medical affairs teams for information directly related to treatment decisions.
Hunger for information: Doctors say information provision services are the most important medical affairs services.
Teams have the right focus: Nearly all teams earned moderately high performance scores and high satisfaction scores in the areas most important to doctors.
All teams lagging in one area: According to the doctors surveyed, there’s one service that every team covered in the report needs to improve.
US doctors less likely to prefer frequent interactions: Only 40% of US doctors prefer to interact with medical affairs teams more than once per quarter compared to 50% in Europe.
Electronic communication on the rise: A significant number of doctors identified electronic communication as an area for improvement.

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams—answering important questions like:

What do oncologists need?

How, and how often are they using your medical affairs team?
What services do they consider most important?
How often should you contact them? What channels are best?

Does your medical affairs team deliver?

How memorable are your team’s interactions with oncologists?
How do oncologists rank your team for performance and satisfaction in 12 key areas?
How does your team compare to the competition—in each area, and overall?

What needs improvement?

Are you delivering the services that are most important to oncologists?
Where do you need to improve?
How can your team enhance its services?

Based on Interviews with Practicing Oncologists

We surveyed 100 infectious disease specialists, chosen from the largest community of validated physicians in the world.

All respondents:

Have been practicing for between 3 and 35 years
See at least 5 patients with NSCLC in a typical month
Devote at least 50% of their time to direct patient care
Have interacted with at least one listed product’s medical affairs team in the last 6 months.

We conducted the survey between April 12th and April 26th, 2016.

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Table of Contents

1.Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary

2.Current Status of Interactions with Different Medical Affairs Teams

2.1.Interactions in the past 6 months with Medical Affairs teams for each product

2.2.Current frequency of interactions with medical affair teams for each product

3.Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes

3.1.Evaluation of overall quality of interactions with Medical Affairs teams for each product

3.2.Attribute importance of Medical Affairs teams roles to physicians’ practice

3.3.EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes

3.4.Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams

3.5.Need-Gap analysis by product

4.Preferred Interaction Media, Frequency, and Suggestions for Improvement

4.1.Preferred interaction media and frequency, and suggestions for improvement


Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at

Browse similar reports by category:
Pharmaceuticals & Healthcare

Our Clients